# D&D Pharmatech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/d-d-pharmatech

- Industry: Biotechnology
- Headquarters: Seongnam, South Korea
- Website: www.ddpharmatech.com
- Total disclosed funding: $187M
- Latest round: Series C (Oct 8, 2021)
- Investors on record: 12

## About

Based in Seongnam-si, South Korea, and founded in 2014 by CEO Seulki lee, D&D Pharmatech Inc. operates as a pharmaceutical company that develops therapeutics for the treatment of neurodegenerative diseases, fibrotic diseases, and metabolic diseases, as well as molecular imaging. In May 2024, D&D Pharmatech Inc. raised KRW 36.3 billion in an IPO, selling 1.1 million shares at KRW 33,000 per share, above the expected price range of KRW 22,000 and KRW 26,000 on the KOSDAQ. 

D&D Pharmatech Inc. focuses on drug discovery program, targeting metabolic diseases, including obesity, diabetes, and non-alcoholic steatohepatitis (NASH). Its PEGylation and oral peptide platform technologies to develop DD01, which is a GLP-1/Glucagon dual receptor agonist and reduces liver fat content in patients with obesity, diabetes, and NASH. The company offers neurological research into treatments for neurodegenerative diseases such as Parkinson's and Alzheimer's. Its lead asset, NLY01, is a GLP-1R agonist targeting neuroinflammation across multiple therapeutic areas.

## Funding rounds

- Series C, Oct 8, 2021, $49M — Korea Investment & Securities, Praxis Capital Partners, Kudos Ventures, DS Asset Management
- Series B, Jun 7, 2019, $119M — LB Investment, InterVest, Smilegate Investment, Magna Investment, Octave Life Sciences
- Series A, Apr 5, 2018, $18M — LB Investment, InterVest, Smilegate Investment, Maryland Venture Fund, Magna Investment, Geon Investment, Octave Life Sciences, DongKoo Bio&Pharma

## Investors

- LB Investment (https://capitalatlas.ai/funds/lb-investment) — Series A, Series B
- InterVest (https://capitalatlas.ai/funds/intervest) — Series A, Series B
- Smilegate Investment (https://capitalatlas.ai/funds/smilegate-investment) — Series A, Series B
- Maryland Venture Fund (https://capitalatlas.ai/funds/maryland-venture-fund) — Series A
- Magna Investment (https://capitalatlas.ai/funds/magna-investment) — Series A, Series B
- Geon Investment (https://capitalatlas.ai/funds/geon-investment) — Series A
- Octave Life Sciences — Series A, Series B
- DongKoo Bio&Pharma — Series A
- Korea Investment & Securities (https://capitalatlas.ai/funds/korea-investment-securities) — Series C
- Praxis Capital Partners (https://capitalatlas.ai/funds/praxis-capital-partners) — Series C
- Kudos Ventures (https://capitalatlas.ai/funds/kudos-ventures) — Series C
- DS Asset Management (https://capitalatlas.ai/funds/ds-asset-management) — Series C